| 杜 婧,邓雁北,高 颖,项晓燕,李文亚.瑞舒伐他汀钙与非诺贝特联合治疗血脂异常的疗效及对肝肾功能的影响[J].,2021,(6):1077-1080 |
| 瑞舒伐他汀钙与非诺贝特联合治疗血脂异常的疗效及对肝肾功能的影响 |
| Effect of Rosuvastatin Calcium Combined with Fenofibrate in the Treatment of Dyslipidemia and Its Effect on Liver and Renal Function |
| 投稿时间：2020-06-29 修订日期：2020-07-25 |
| DOI：10.13241/j.cnki.pmb.2021.06.017 |
| 中文关键词: 瑞舒伐他汀钙 非诺贝特 血脂异常 肝功能 肾功能 不良反应 |
| 英文关键词: Rosuvastatin calcium Fenofibrate Dyslipidemia Liver function Renal function Adverse reactions |
| 基金项目:江苏省卫生厅医学创新团队科技项目(K201106) |
|
| 摘要点击次数: 1036 |
| 全文下载次数: 1085 |
| 中文摘要: |
| 摘要 目的：观察瑞舒伐他汀钙与非诺贝特联合治疗血脂异常的疗效及对肝肾功能的影响。方法：选择2017年1月至2019年6月间我院门诊收治的127例血脂异常患者，随机分为研究组（n=63）和对照组（n=64），在针对合并症给予对症治疗的基础上，对照组采用瑞舒伐他汀钙治疗，研究组在对照组基础上联合非诺贝特治疗。观察两组血脂水平、 肝肾功能、临床效果以及不良反应发生率。结果：治疗后，两组总胆固醇（TC）、低密度脂蛋白胆固醇（LDL-C）、甘油三酯（TG）水平低于治疗前（P＜0.05），且研究组低于对照组（P＜0.05）；高密度脂蛋白胆固醇（HDL-C）、丙氨酸氨基转移酶（ALT）水平均高于治疗前（P＜0.05），且研究组高于对照组（P＜0.05）；两组治疗前后尿素氮（UN）、肌酐（Cr）比较差异无统计学意义（P＞0.05）；研究组的总有效率为92.06%（58/63），高于对照组的79.69%（51/64），差异有统计学意义（P＜0.05）；研究组不良反应发生率为11.11%（7/63），稍高于对照组的9.38%（6/64），但差异无统计学意义（P＞0.05）。结论：在瑞舒伐他汀钙基础上联合非诺贝特治疗血脂异常可提高临床有效率，可增强调节血脂的作用，其安全性较好，但对血脂异常患者的肝功能影响较大，临床可视患者情况合理选用用药方案。 |
| 英文摘要: |
| ABSTRACT Objective: To observe the clinical effects of rosuvastatin calcium combined with fenofibrate therapy on dyslipidemia and its effect on liver and renal function. Methods: 127 patients with dyslipidemia in outpatient department of our hospital from January 2017 to June 2019 were selected, which were divided into study group(n=63) and control group(n=64) according to random number table method, the control group was treated with rosuvastatin calcium on the basis of symptomatic treatment for the complications, the study group was treated with fenofibrate on the basis of control group. Blood lipid levels, liver and renal function, clinical effect and adverse reaction rate of the two groups were observed. Results: After the treatment, the levels of total cholesterol(TC), low density lipoprotein cholesterol (LDL-C) and triacylglycerol (TG) were significantly lower than those before treatment(P<0.05), which in the study group were significantly lower than in the control group (P<0.05); High density lipoprotein cholesterol (HDL-C) and alanine transferase (ALT) were significantly higher than that before treatment (P<0.05), which in the study group were significantly higher than the control group (P<0.05); There were no significant difference in the levels of urea nitrogen (UN) and creatinine (Cr)(P>0.05); The total effective rate of the study group was 92.06%（58/63）, significantly higher than that in the control group of 79.69%（51/64）, the difference was statistically significant (P<0.05); The incidence rate of adverse reactions was 11.11%（7/63） in the study group, slightly higher than that of the control group of 9.38%（6/64）, while the difference was not statistically significant (P>0.05). Conclusion: On the basis of rosuvastatin calcium combined with fenofibrate in the treatment of dyslipidemia can improve the clinical efficiency, enhance the role of regulating blood lipid, its safety is better, but it has a greater impact on the liver function of patients with dyslipidemia, and the clinical use of drugs can be reasonable according to the situation of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
